Skip to main content
Premium Trial:

Request an Annual Quote

Consolidation History in the Bioinformatics Sector, as Tracked by BioInform, 2000-2003


March: Paracel acquired by Celera Genomics (deal worth $283M)

August: Oxford Molecular acquired by Pharmacopeia (deal worth $27M)

September: Neomorphic acquired by Affymetrix (deal worth $70M)

October: Empaheon acquired by eBioinformatics (deal worth $11M)

December: Proteome acquired by Incyte (deal worth $77M)


Rosetta Inpharmatics acquired by Merck (deal worth $620M)

July: Synomics acquired by Accelrys (deal worth $4M)

July: Momentum acquired by Cellomics

November: Genomica acquired by Exelixis (deal worth $110M)


NetGenics acquired by Lion Bioscience (deal worth $17M)

February: ProteoMetrics closes, software acquired by Genomic Solutions (value not disclosed)

March: Entigen ceases operations

March: DoubleTwist closes

December: InforMax acquired by Invitrogen (deal worth $42M)


Structural Genomics, GeneFormatics plan merger

February: Viaken Systems closes

February: Phase-it acquired by Europroteome (value not disclosed)

March: Molecular Mining closes

April: Argentys (formerly Blackstone) acquired by TurboWorx (value not disclosed)

April: LabBook discontinues retail operations; Rescentris licenses technology


Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.